🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Michael Newton

AstraZeneca (Japan)

ORCID: 0000-0003-1649-4116
Environmental ScienceAgricultural and Biological Sciences

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

1in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology
Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

Papers

Driven by 5 papers. Top paper: Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer.

1324 citations

Corinne Faivre‐Finn, Jhanelle E. Gray, David Vicente, David Planchard, Luis Paz‐Ares +20 more

471 citations

David Vicente, Takayasu Kurata, David Planchard, Luis Paz‐Ares, Johan Vansteenkiste +18 more

113 citations

Scott Antonia, Yi-Long Wu, Byoung Chul Cho, Piruntha Thiyagarajah, Helen Mann +3 more

6 citations

Benjamin Levy, H. Horinouchi, J. Yu, Elizabeth M. Grainger, P. Phuong +4 more

2 citations

Lindsey Lammlin, Sofia Gonzalez-Nolde, Scarlet Howser, I Smith, Luke Stasikelis +94 more